Trial reportThe Journal of infectious diseases2007
Antibody responses to vaccinia membrane proteins after smallpox vaccination.
Trial report in The Journal of infectious diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- Immunoinformatics design of multivalent epitope vaccine against monkeypox virus and its variants using membrane-bound, enveloped, and extracellular proteins as targets.Frontiers in immunology · 2023Article
- Contriving multi-epitope vaccine ensemble for monkeypox disease using an immunoinformatics approach.Frontiers in immunology · 2022Article
- Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.Journal of virology · 2016Article
- Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.Vaccine · 2015Review
- Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Immunosignatures can predict vaccine efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.Journal of virology · 2013Article
- Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Journal of virology · 2013Article
- Orthopoxvirus targets for the development of new antiviral agents.Antiviral research · 2012Review
- Capturing the natural diversity of the human antibody response against vaccinia virus.Journal of virology · 2011Article
- The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Virology · 2010Article
- Article
- Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge.Expert review of vaccines · 2010Article
- Article
- Article
- Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.Journal of virology · 2009Article
- Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.Clinical and vaccine immunology : CVI · 2009Article
- Evaluation of smallpox vaccines using variola neutralization.The Journal of general virology · 2009Article
- Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.Journal of virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundVaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized.
methodsPre- and postvaccination (day 26-30) serum specimens from 80 VV vaccine recipients were examined for immunoglobulin G antibodies specific for B5, A33, A27, and L1 by enzyme-linked immunosorbent assay (ELISA). Responses were compared between vaccinia-naive and previously vaccinated (nonnaive) recipients and between nonnaive recipients of undiluted or 1 : 10 diluted vaccine.
resultsVV vaccination elicited anti-A33 and anti-A27 antibodies in nearly all vaccinia-naive subjects (100% and 93%, respectively). Preexisting antibodies were commonly detected in nonnaive subjects (for anti-B5, 68%; for anti-A33, 59%; for anti-A27, 38%; and for anti-L1, 10%). Anti-B5 antibodies were strongly boosted by undiluted vaccine (geometric mean titer [GMT], 151 vs. 1010 for pre- vs. postvaccination; P<.001), whereas anti-L1 antibody responses were less robust (detection rate, 31%; GMT, 75) in nonnaive subjects. Diluted vaccine elicited antibody responses that were similar to those elicited by undiluted vaccine.
conclusionsVaccination with VV elicits long-lived specific antibody responses directed against VV membrane proteins that vary by previous vaccination status but not with respect to 10-fold dilution of vaccine. B5, A33, and A27 should be considered for inclusion in future human orthopoxvirus subunit vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.